XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Study sponsor: Xencor, Inc. · XNCR
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-06-10Actual
Enrollment · participants72Actual
Source updated2026-05-05Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.